

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Stephen M. Strittmatter  
SERIAL NUMBER: 09/485,601      Examiner: Sharon L. Turner  
FILING DATE: May 4, 2000      Art Unit: 1647  
FOR: CENTRAL NERVOUS SYSTEM AXON REGENERATION USING RHO PROTEIN INHIBITORS

**MAIL STOP IDS**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the first Office Action but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. Accordingly, a fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by


APPLICANTS: Stephen M. Strittmatter  
U.S.S.N.: 09/485,601

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.: 23380-601 NATL.


Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Scott D. Miller, Reg. No. 43,803  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPPEO, P.C.  
The Chrysler Center  
666 Third Avenue  
New York, New York 10017  
Tel: (212) 935-3000  
Fax: (212) 983-3115

Dated: November 4, 2003

NYC 273871v1



Please type a plus sign (+) in this box  +

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	09/485,601
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date	05/04/00
(use as many sheets as necessary)		First Named Inventor	Strittmatter
		Group Art Unit	1647
		Examiner Name	Turner
		Attorney Docket Number	23380-601 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C10	Gebbink et al. (1997). <i>J. Cell Biology</i> 137: 1603-1613.			
	C11	Kozma et al. (1997). <i>Molecular and Cellular Biology</i> 17: 1201-1211.			
	C12	Lamoureux et al. (1997). <i>J. Cell Science</i> 110: 635-641.			

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.